SEC Form 4 · accession 0001140361-18-030008
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Baffi
Officer — EVP, Technical Operations
Period of report
Jun 22, 2018
Accepted (ET)
Jun 26, 2018 · 8:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 22, 2018 | M | 6,949 | $14.39 | A | 90,225 | D | |
| Common StockF1 | Jun 22, 2018 | S | 6,621 | $99.00 | D | 83,604 | D | |
| Common StockF1 | Jun 22, 2018 | S | 328 | $99.01 | D | 83,276 | D | |
| Common Stock | holding | — | — | — | 77,055 | I | Shares held by Baffi Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F2 | $14.39 | Jun 22, 2018 | M | 6,949 | D | Nov 12, 2009 | May 11, 2019 | Common Stock | 6,949 | 0 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on March 6, 2018.
- F2Reflects the number of options outstanding after the transactions from this specific stock option grant.